AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00364910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants meet with a therapist for three to five sessions brief exposure-based CBT.
Study NCT02287961 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard proctologic examination
Description: (with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
Study NCT02675491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6051b
Description: Drug: DS-6051b 400 mg or 800 mg daily
Study NCT00471107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC brain polarization
Description: 0.08 mA/cm2
Study NCT00471107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC brain polarization
Description: 0.08 mA/cm2
Study NCT01123564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
Study NCT01123564 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Argon laser treatment
Description: Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
Study NCT00787488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Every 3 weeks
Study NCT00793611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral therapy standard of care
Description: controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
Study NCT00793611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy standard of care
Description: controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
Study NCT00793611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnotherapy
Description: Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
Study NCT04011709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation System + VR647 Smart Card 3 Secs
Description: 3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
Study NCT02287961 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: High resolution anoscopy
Description: at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
Study NCT02287961 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy(ies) during High Resolution Anoscopy
Description: only if lesion suggestive of AIN detected during High Resolution Anoscopy
Study NCT04011709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation System + VR647 Smart Card 2 Secs
Description: 3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
Study NCT04011709 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation System + VR647 Smart Card 4 Secs
Description: 3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
Study NCT04516200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation and traditional physical therapy program
Description: Transcranial stimulation will be applied only for the study group.
Study NCT04516200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program
Description: sensory training and balance training
Study NCT04516200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: designed physical therapy program
Description: sensory training and balance training
Study NCT00364910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational session and treatment as usual
Description: Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
Study NCT03358628 — intervention group
Intervention type: OTHER
Intervention: Molecular Profiling & In Vivo drug testing in PDX
Description: Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
Study NCT03077048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketosteril®
Description: Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
Study NCT02031900 — intervention group
Intervention type: DEVICE
Intervention: NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit
Description: The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
Study NCT03291002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102
Description: CV8102 alone
Study NCT03291002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102 + anti-PD-1 therapy
Description: CV8102 in combination with standard of care anti-PD-1 therapy
Study NCT03063255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obturator block
Description: Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
Study NCT03063255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular block
Description: Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
Study NCT01025336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
Study NCT01025336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
Study NCT02975648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational model + follow up
Description: Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
Study NCT02975648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Hospital health professionals offered orientation on care after discharge
Study NCT02296346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoluMedrol
Description: Infusion of drug subcutaneously, once a month.
Study NCT02296346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
Study NCT02287961 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Resolution Anoscopy biannually
Description: Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
Study NCT03031821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Alafenamide
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir Alafenamide
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
Study NCT03031821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration
Study NCT03685305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with hunger reduction strategy
Description: Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
Study NCT03685305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet without hunger reduction strategy
Description: Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablet orally on Day 1.
Study NCT03532282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ONLINE ONLY
Description: Access to an online cognitive behavioral therapy for insomnia
Study NCT03532282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPPED CARE
Description: A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm (checklist). Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment
Study NCT03410875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
Study NCT03410875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
Study NCT02744677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV
Description: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV in the pulmonic position
Study NCT02744677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV
Description: SAPIEN 3 THV in the pulmonic position
Study NCT02744677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 Ultra RESILIA THV
Description: SAPIEN 3 Ultra RESILIA THV in the pulmonic position
Study NCT04236453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablet orally on Day 1.
Study NCT02242110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERRT-Bipolar Disorder
Description: The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
Study NCT02817204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
Study NCT02817204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
Study NCT02162979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 50mg BID for 2 weeks
Study NCT02162979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01668069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
Study NCT00474253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
Study NCT00474253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Single bolus IV dose of 1.0 mg/kg succinylcholine
Study NCT00474253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Single bolus IV dose of 1.2 mg/kg rocuronium
Study NCT01287117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Study NCT01287117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Study NCT01720251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SC injections of placebo on days 1, 7, 14, 28 and 56
Study NCT01720251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT low dose
Description: SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
Study NCT01720251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT full dose
Description: SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
Study NCT04100525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing intervention plus follow up
Description: Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
Study NCT04100525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological testing intervention plus follow up
Description: Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
Study NCT02277886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium alginate
Description: oral suspension, 50mg/ml, 20ml once at bed time
Study NCT02277886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40mg/tablet, one tablet once before breakfast
Study NCT02277886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: 40mg/tablet, one tablet once before breakfast
Study NCT01357239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT01357239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04937257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
Study NCT04937257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-module
Description: The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
Study NCT03484026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioFe
Description: BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
Study NCT04471220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
Study NCT02291341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine Delayed-Release Capsules 60 mg
Study NCT02291341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta®
Description: 60 mg capsule of Eli Lilly and Company
Study NCT01152099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Bandaging
Description: Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied.